Øystein Rekdal
Chief Executive Officer bij LYTIX BIOPHARMA
Vermogen: 79 132 $ op 31-03-2024
Profiel
Øystein Rekdal is the founder of Lytix Biopharma AS, a company founded in 2003.
He holds the title of Chief Executive Officer at Lytix Biopharma AS starting in 2019.
Dr. Rekdal's current job is as a Professor at the University of Tromso.
He previously worked as a Director at Prophylix AS.
Dr. Rekdal obtained a doctorate degree from the University of Tromso.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
LYTIX BIOPHARMA AS
0.35% | 26-08-2022 | 139 963 ( 0.35% ) | 79 132 $ | 31-03-2024 |
Actieve functies van Øystein Rekdal
| Bedrijven | Functie | Begin |
|---|---|---|
| LYTIX BIOPHARMA | Chief Executive Officer | 11-09-2019 |
| University of Tromso | Corporate Officer/Principal | - |
Eerdere bekende functies van Øystein Rekdal
| Bedrijven | Functie | Einde |
|---|---|---|
Prophylix AS
 Prophylix AS Pharmaceuticals: MajorHealth Technology Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway. | Director/Board Member | - |
Opleiding van Øystein Rekdal
| University of Tromso | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| LYTIX BIOPHARMA | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Prophylix AS
Prophylix AS Pharmaceuticals: MajorHealth Technology Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway. | Health Technology |
